LANSING, Mich., March 20, 2014 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB:KBLB) ("Company"), the leading developer of advanced spider silk based fibers, today announced that its scientific evaluation team performed an onsite assessment and evaluation, at the request of the Company, of its genetically engineered recombinant spider silk, Monster Silk™, production ramp up. This production ramp up follows closely on the heels of the Company's successful pilot production program, which finished in late 2013. The scientific evaluation team reported that the ramp up program is on track for large scale production of Monster Silk™. The team's report also included specific recommendations for accelerating commercial scale production and for completing the transition from pilot production to commercial scale production.
"The scientific evaluation team's findings reinforce our belief that this important program is working and warrants that we commit additional resources to our scale up of Monster Silk™ production. This evaluation encourages us that we are on the right track to achieve our goal of large scale production. More importantly, the team found areas where we can improve our production efficiency in order to reach that goal. We have already started to put these plans in place to strengthen the Monster Silk™ production program," said Company Founder and CEO, Kim K. Thompson.
The goal of this program is to produce Monster Silk™ in metric ton quantities.
About Kraig Biocraft Laboratories, Inc.
Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a fully reporting biotechnology company is the leading developer of genetically engineered spider silk based fiber technologies. The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.
Cautionary Statement Regarding Forward Looking Information
Statements in this press release about the Company's future and expectations other than historical facts are "forward-looking statements." These statements are made on the basis of management's current views and assumptions. As a result, there can be no assurance that management's expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as "believes," "plans," "expects," "anticipates," "foresees," "estimated," "hopes," "if," "develops," "researching," "research," "pilot," "potential," "could" or other words or phrases of similar import. Forward looking statements include descriptions of the Company's business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements.
This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.
CONTACT: Ben Hansel, Hansel Capital, LLC. (720) 288-8495 ir@KraigLabs.com
Source:Kraig Biocraft Laboratories, Inc